Respiri - NC rollout to expand wheezo market potential
Respiri has started patient onboarding for a major North Carolina (NC)-based healthcare organisation (the initial contract was signed in August 2022). The agreement applies to chronic obstructive pulmonary disease (COPD) patients for the full service wheezo remote patient monitoring (RPM) programme. We believe positive feedback or a strong display of utility from initial patients will generate an opportunity to accelerate wheezo’s adoption across broader healthcare groups, in line with commercialisation efforts. Our valuation is unchanged at A$0.24 per share.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- Respiri - NC rollout to expand wheezo market potential09 Jan 2023